ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2025
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • 2020-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstracts tagged "interferon"

  • Abstract Number: 0951 • ACR Convergence 2024

    A Feedback Loop Involving mtDNA, Platelets and Neutrophil Extracellular Traps Amplifies Inflammation in Systemic Sclerosis

    Stavros Giaglis1, Diego Kyburz2 and Ulrich Walker3, 1Experimental Rheumatology Laboratory, University of Basel, Basel, Switzerland, 2University Hospital Basel, Basel, Switzerland, 3Basel University Hospital, Basel, Switzerland

    Background/Purpose: Mitochondria are essential eucaryotic cell organelles with several bacterial features, such as a double-stranded circular genome with hypomethylated CpG areas (1). A fundamental role of…
  • Abstract Number: 1766 • ACR Convergence 2024

    STAT2-Associated Type I Interferonopathy: A Masquerade of Infectious Susceptibility

    Conor Gruber1, Angelica Lee2, Sofija Buta2, Marta Martin Fernandez2, Veronique Houdouin3, Jean-Laurent Casanova4, Alice Hadchouel5, Jacinta Bustamante5 and Dusan Bogunovic2, 1Mount Sinai Hospital, New York, NY, 2Columbia University, New York, NY, 3Robert Debré Hospital, Paris, France, 4Rockefeller University, New York, NY, 5Hôpital Necker-Enfants Malades, Paris, France

    Background/Purpose: Type I IFN (IFN-I) signaling is a potent inflammatory pathway fundamental to antiviral immunity. In humans, loss of IFN-I activity underlies severe viral disease,…
  • Abstract Number: 2385 • ACR Convergence 2024

    Increased Type I Interferon Inducible Genes Expression in the Peripheral Blood of Patients Presenting Cutaneous Lupus Erythematosus Manifestations

    Anastasia- Bilio Chronopoulou1, Maria Gerochristou2, Sylvia Raftopoulou3, Alexander Stratigos4 and Clio Mavragani5, 1National and Kapodistrian University of Athens, Athens, Greece, 2Andreas Syggros Hospital, National and Kapodistrian University of Athens, Athens, Greece, 3Molecular and Applied Physiology Unit, Department of Physiology, School of Medicine, National and Kapodistrian University of Athens., Athens, Greece, 41st Department of Dermatology-Venereology, Faculty of Medicine, Andreas Sygros Hospital, National and Kapodistrian University of Athens, Athens, Greece, 5Department of Physiology and Pathophysiology, School of Medicine, National and Kapodistrian University of Athens., Athens, Greece

    Background/Purpose: Cutaneous Lupus Erythematosus (CLE) is a chronic autoimmune skin disease characterized by a spectrum of cutaneous manifestations resulting from immune dysregulation and inflammation. While…
  • Abstract Number: 0608 • ACR Convergence 2023

    Efficacy of Cenerimod in Patients with High IFN-1 Gene Expression Signature and High Anti-dsDNA Antibody Levels: Post-hoc Analysis from a Phase 2 Study

    Anca Askanase1, David D'Cruz2, Kenneth Kalunian3, Joan Merrill4, Sandra Navarra5, Clélia Cahuzac6, Peter Cornelisse6, Daniel Strasser6, Luba Trokan7 and Ouali Berkani8, 1Columbia University Medical Center, New York, NY, 2Guy's and St Thomas' NHS Foundation Trust, London, United Kingdom, 3University of California San Diego, La Jolla, CA, 4Oklahoma Medical Research Foundation, Oklahoma City, OK, 5University of Santo Tomas Hospital, Joint and Bone Center, Manila, Philippines, 6Idorsia Pharmaceuticals Ltd., Allschwil, Switzerland, 7Idorsia Pharmaceuticals Ltd. at time of data generation, Allschwil, Switzerland, 8IDORSIA, Allschwil, Switzerland

    Background/Purpose: Cenerimod is an orally active, selective sphingosine 1-phosphate (S1P) 1 receptor modulator under investigation for the treatment of systemic lupus erythematosus (SLE). In the…
  • Abstract Number: 1271 • ACR Convergence 2023

    Upregulation of IFNγ-Response Genes in Monocytes and T Cells Identified by Single-Cell Transcriptomics in Patients with Anti-CCP Antibody-Positive Rheumatoid Arthritis (RA)

    Bong-Ki Hong1, Sungyong You2, Naeun Lee1, Jung Gon Kim3, Kijun Lee4, Ji Hyeon Ju5, Wan-Uk Kim1 and Ho-Youn Kim6, 1The Catholic University of Korea, Seoul, South Korea, 2Cedars-Sinai Medical Center, Los Angeles, CA, 3Inje University Ilsan Paik Hospital, Goyang, South Korea, 4YiPSCELL, Secho, South Korea, 5Division of Rheumatology, Department of Internal Medicine, Seoul St. Mary's Hospital, College of Medicine, The Catholic University of Korea, Seoul, South Korea, 6HoYoun Kim's Clinic for Arthritis Rheumatism, Seoul, South Korea

    Background/Purpose: Recent research has revealed a significant upregulation of IFNγ-related genes in RA patients, though the underlying mechanisms and implications are still unclear. To further…
  • Abstract Number: 2448 • ACR Convergence 2023

    UV Light Exposure Induces a Type I Interferon Dependent Activation and Migration of Inflammatory Dendritic Cells to Local Lymph Nodes

    Xizhang Sun, Jaime Chao, Michael Gerner and Keith Elkon, University of Washington, Seattle, WA

    Background/Purpose: Photosensitivity occurs in ~ 75% of lupus patients. Although ultraviolet (UV) light stimulates Type I interferon (IFN-I) in the skin, why lupus patients are…
  • Abstract Number: 0724 • ACR Convergence 2023

    Synovial Macrophage Subsets Defined by ScRNAseq Demonstrate Sexually Dimorphic Gene Expression in RA and a Mouse Inflammatory Arthritis Model

    Richard Bell, Ewurama Cann, Chao Yang, Accelerating Medicine Partnership Rheumatoid Arthritis, Amit Lakhanpal, Laura Donlin and Lionel Ivashkiv, Hospital for Special Surgery, New York, NY

    Background/Purpose: Macrophages (MФ) play a key pathogenic role in Rheumatoid Arthritis (RA), a disease that exhibits female sex bias. Recent work using scRNAseq has defined…
  • Abstract Number: 1508 • ACR Convergence 2023

    Predicting in Virtual Patients the Efficacy of an Anti IFNa Mab in Cutaneous Lupus Erythematosus

    Vincent Hurez1, Krishnakant Dasika Dasika1, Perrine Soret2, Renee Myers3, Katherine Kudrycki1, Robert Sheehan1, Christina Friedrich11, Sandra Hubert2, Mike Reed1, Emiko Desvaux2, Audrey Aussy2, Laurence Laigle2, Loubna Chadli2, Florian Chassereau2, Sylvain Fouliard2, Glenn Gauderat2 and Philippe Moingeon2, 1Rosa and Co, San Carlos, CA, 2Les Laboratoires Servier SAS, Suresnes, France, 3Les Laboratoires Servier SAS, San Carlos, France

    Background/Purpose: Systemic Lupus Erythematosus (SLE) is a heterogeneous autoimmune disease that requires more specific treatments to target patient subsets. To support precision medicine approaches, we…
  • Abstract Number: 2576 • ACR Convergence 2023

    Rapid Onset of Response in Adult Dermatomyositis Patients Receiving Anti-interferon β (PF-06823859): Results of a Phase 2, Double-blind, Randomized, Placebo-Controlled Study

    Rohit Aggarwal1, Elena Peeva2, Aaron Mangold3, Abigail Sloan2 and Myron Chu2, 1University of Pittsburgh, Pittsburgh, PA, 2Pfizer, Cambridge, MA, 3Mayo Clinic, Scottsdale, AZ

    Background/Purpose: Interferon (IFN) dysregulation is a key feature in the pathogenesis of Dermatomyositis (DM). PF-06823859 is a potent, selective, humanized IgG1 neutralizing antibody directed against…
  • Abstract Number: 0728 • ACR Convergence 2023

    Systemic Lupus Erythematosus B Lymphocyte Responsiveness to Type I and Type III Interferon Is Determined by Donor IFN Status and B Cell Phenotype

    Diana Alzamareh, Mary O'Connell, Jennifer Anolik and Jennifer Barnas, University of Rochester Medical Center, Rochester, NY

    Background/Purpose: Systemic lupus erythematous (SLE) is a heterogenous autoimmune disorder characterized by pathogenic antinuclear antibodies. An interferon (IFN) gene signature and B cell aberrations are…
  • Abstract Number: 1580 • ACR Convergence 2023

    CXCL13+ T Cell Differentiation in Systemic Lupus Erythematosus Is Controlled by Opposing Effects of Aryl Hydrocarbon Receptor and Type I Interferon

    Calvin Law1, Vanessa Wacleche2, Ye Cao3, Arundhati Pillai1, Alice Horisberger4, Sabrina Bracero3, Viktoriya Skidanova3, Zhihan Li3, Ifeoluwakiisi Adejoorin2, Isaac Benque3, Diana Pena Nunez3, Daimon Simmons2, Joshua Keegan4, Lin Chen3, John Sowerby3, Accelerating Medicines Partnership (AMP): RA/SLE2, Elena Massarotti2, Karen Costenbader4, Michael Brenner4, James Lederer4, Judd Hultquist1, Jaehyuk Choi1 and Deepak Rao2, 1Northwestern University Feinberg School of Medicine, Chicago, IL, 2Brigham and Women's Hospital, Boston, MA, 3Brigham and Women's Hospital, Boston, MA, 4Brigham and Women's Hospital and Harvard Medical School, Boston, MA

    Background/Purpose: Expansion of B cell-helper T cells including T follicular helper (Tfh) and T peripheral helper (Tph) cells is a prominent feature of systemic lupus…
  • Abstract Number: 0733 • ACR Convergence 2023

    Global Identification of Lupus Genetic Risk Variants Facilitating the Type I Interferon Pathway Through CRISPR-based Genomic Screening

    Guojun Hou1, Xinyi Zhu1, Yutong Zhang1, Zhaorui Cheng1 and Nan Shen2, 1Shanghai Institute of Rheumatology, Renji Hospital, School of Medicine, Shanghai Jiao Tong University (SJTUSM), Shanghai, China, 2Shanghai Jiao Tong University School of Medicine, Shanghai, China

    Background/Purpose: Genome-Wide Association Studies (GWAS) have unveiled over 1000 risk variants for lupus, predominantly situated in non-coding genomic regions. Their functional roles, especially their potential…
  • Abstract Number: 1586 • ACR Convergence 2023

    Keratinocyte VISTA Suppresses Skin IFN-I Production by Regulating DNA Damage Repair and Cytosolic DNA Sensing

    Zachary Peters1, Lindsay Mendyka2, Sicong Shan1, William Rigby3, Christopher Burns4, Randolph Noelle5 and Sladjana Skopelja-Gardner4, 1Dartmouth College, Hanover, NH, 2Dartmouth Hitchcock, Lebanon, NH, 3Dartmouth-Hitchcock, Norwich, VT, 4Dartmouth Hitchcock Medical Center, Lebanon, NH, 5Geisel School of Medicine at Dartmouth, Hanover, NH

    Background/Purpose: Persistent production of type I interferons (IFN-Is) is one of the hallmarks of lupus skin disease that is exacerbated by ultraviolet (UV) light. We…
  • Abstract Number: 0762 • ACR Convergence 2023

    Liver Disease Is a Common Feature of HA20 That Causes Significant Morbidity Associated with Interferon Induction

    Magdalena Harasimowicz1, Deborah Stone2, Manuel Carpio Tumba1, Tina Romeo2, Urekha Karri1, Patrycja Hoffmann3, Helen Leavis4, Alexander Miethke5, Theo Heller2, Anjali Rai2, Ivona Aksentijevich2, amanda ombrello6, Daniel Kastner7 and Daniella Schwartz1, 1University of Pittsburgh, Pittsburgh, PA, 2NIH, Bethesda, MD, 3NIH, Vienna, VA, 4Infection Immunity Utrecht, Utrecht, Netherlands, 5Cincinnati Children's Hospital, Cincinnati, OH, 6National Institutes of Health, Rockville, MD, 7National Human Genome Research Institute, Bethesda, MD

    Background/Purpose: Heterozygous loss-of-function TNFAIP3 mutations cause A20 haploinsufficiency (HA20), an early-onset immune dysregulatory disease1. While HA20 was initially described as an inherited form of Behcet’s…
  • Abstract Number: 1587 • ACR Convergence 2023

    Mitochondrial Z-DNA and ZBP1 Drive Autoimmune Photosensitivity

    Benjamin Klein, Mack Reynolds, Bin Xu, Mehrnaz Gharaee-Kermani, Amanda Victory, Shannon Loftus, Mary O'Riordan and J. Michelle Kahlenberg, University of Michigan, Ann Arbor, MI

    Background/Purpose: Autoimmune photosensitivity is observed in type I Interferon (IFN) mediated diseases such as systemic and cutaneous lupus erythematosus (SLE/CLE) and dermatomyositis. Type I IFN…
  • « Previous Page
  • 1
  • …
  • 6
  • 7
  • 8
  • 9
  • 10
  • …
  • 19
  • Next Page »
Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

Embargo Policy

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2026 American College of Rheumatology